Stephan Christgau
Chairman at Venture Cup Foundation
Network origin in Stephan Christgau first degree
| Entity | Entity type | Industry | |
|---|---|---|---|
Novo Seeds
 Novo Seeds Investment ManagersFinance Novo Seeds (Novo Seeds) is a venture capital operating division of Novo Nordisk Fonden. The firm was established in 2007, and is headquartered in Hellerup, Denmark.
16
| Operating Division | Investment Managers | 16 |
Scenic Biotech BV
 Scenic Biotech BV Miscellaneous Commercial ServicesCommercial Services Scenic Biotech BV is using genomics to develop innovative therapies for patients affected by severe diseases. The company was founded by Thijn Brummelkamp and Sebastian Nijman and is headquartered in Amsterdam, Netherlands.
11
| Holding Company | Miscellaneous Commercial Services | 11 |
IO Biotech ApS
 IO Biotech ApS BiotechnologyHealth Technology IO Biotech ApS operates as a clinical stage biotech company. It develops immunotherapy for cancer by targeting a mechanism used by tumour cells to evade immune responses. The company was founded by Mai-Britt Zocca, Mads Hald Andersen, Inge Marie Svane, Anders Ljungqvist and Per Thor Straten and is headquartered in Copenhagen, Denmark.
9
| Subsidiary | Biotechnology | 9 |
Novo Holdings A/S (Investment Company)
 Novo Holdings A/S (Investment Company) Financial ConglomeratesFinance Novo Holdings A/S (Investment Company) (Novo Holdings-IC) is the investment portfolio division of Novo Holdings A/S, a holding company headquartered in Hellerup, Denmark. They are ultimately owned by Novo Nordisk Fonden (Novo Nordisk Foundation). Founded in 1999, Novo Holdings-IC manages a broad portfolio of the Foundation’s financial assets.
5
| Operating Division | Financial Conglomerates | 5 |
iSD Immunotech ApS
 iSD Immunotech ApS BiotechnologyHealth Technology iSD Immunotech ApS develops immunoregulatory peptides and proteins. It conducts research and development on immunoregulatory peptides for possible applications and commercialization. The company was founded by Peter Samuel Wulff, Shervin Bahrami, Finn Skou Pedersen, Mogens Ryttergård Duch, Lars Jørgen Østergaard, Martin Tolstrup, and Martin Thygesen on August 9, 2007 and is headquartered in Aarhus, Denmark.
5
| Holding Company | Biotechnology | 5 |
Octarine Bio IVS
 Octarine Bio IVS BiotechnologyHealth Technology Octarine Bio IVS engages in the development of cannabinoid and psychedelic tryptamine derivatives. Its other activities include synthetic biology research. The company was founded by Nicholas Stuart William Milne on September 12, 2018 and is headquartered in Copenhagen, Denmark.
4
| Holding Company | Biotechnology | 4 |
| Public Company | Pharmaceuticals: Major | 3 | |
Forendo Pharma Oy
 Forendo Pharma Oy Pharmaceuticals: MajorHealth Technology Forendo Pharma Oy provides novel pharmaceutical treatments for endometriosis and low testosterone levels. Its product fispemifene is the first selective estrogen receptor modulator designed only for men, which helps for the treatment of symptoms of low testosterone, in phase II clinical studies in men with secondary hypogonadism; fispemifene has normalized the low testosterone levels. Its 17HSD1-inhibitor focuses on endometriosis, is a potent and selective lead compounds demonstrated in vivo proof of efficacy in disease model of endometriosis. The company was founded by Risto Arvo Sakari Lammintausta in 2013 and is headquartered in Turku, Finland.
2
| Subsidiary | Pharmaceuticals: Major | 2 |
Eir Ventures Danmark ApS
1
| Subsidiary | Investment Managers | 1 |
Venture Cup Foundation
1
| Private Company | 1 |
Chart of Companies connected to the second degree
Multi-company connection
Companies connected to Stephan Christgau via their personal network
| Company | Sector | Related people | Main position |
|---|---|---|---|
| IO BIOTECH, INC. | Biotechnology | Director/Board Member Chairman Director/Board Member Director/Board Member Founder Director/Board Member Founder Founder | |
Novo Holdings AS (Denmark)
 Novo Holdings AS (Denmark) Financial ConglomeratesFinance Novo Holding A/S provides financial investments and manages the Novo Nordisk Foundation?s assets. It offers seed and venture capital to development stage companies and takes ownership positions in companies within life science and biotechnology. The company was founded on September 8, 1999 and is headquartered in Hellerup, Denmark. | Financial Conglomerates | Corporate Officer/Principal Chief Executive Officer Corporate Officer/Principal Chief Investment Officer Corporate Officer/Principal Corporate Officer/Principal Chief Investment Officer Corporate Officer/Principal | |
| University of Copenhagen | College/University | Graduate Degree Doctorate Degree Doctorate Degree Graduate Degree Doctorate Degree Doctorate Degree Corporate Officer/Principal Doctorate Degree | |
| Technical University of Denmark | College/University | Chairman Graduate Degree Graduate Degree Graduate Degree Graduate Degree | |
Avilex Pharma ApS
 Avilex Pharma ApS Pharmaceuticals: MajorHealth Technology Avilex Pharma ApS develops and produces drugs to treat brain damage with the uses of dimeric ligands. It also develops novel inhibitors to target a range of unmet medical needs. The firm uses dimeric ligands that targets intracellular with unprecedented potency. The company was founded by Kristian Strømgaard and Anders Bach on December 27, 2012 and is headquartered in Copenhagen, Denmark. | Pharmaceuticals: Major | Director/Board Member Chairman Chairman Chairman Director/Board Member | |
Novo Principal Investments
 Novo Principal Investments Investment ManagersFinance Novo Principal Investments (Novo Principal) is a private equity operating division of Novo Nordisk Fonden. The firm was established in 1999, and is headquartered in Hellerup, Denmark. | Investment Managers | Private Equity Investor Private Equity Investor Private Equity Investor Private Equity Investor | |
| NOVO NORDISK A/S | Pharmaceuticals: Major | Chairman Chairman Corporate Officer/Principal | |
Biosyntia ApS
 Biosyntia ApS BiotechnologyHealth Technology Biosyntia ApS provides services in synthetic biology and metabolic engineering fields. It offers biocatalysts for fermentation of fine chemicals. The company was founded by Andreas Hougaard Laustsen, Morten Otto Alexander Sommer, and Hans Jasper Genee in 2012 and is headquartered in Copenhagen, Denmark. | Biotechnology | Director/Board Member Director/Board Member Director/Board Member | |
Affinicon ApS
 Affinicon ApS Pharmaceuticals: MajorHealth Technology Affinicon ApS operates as a biotechnology company. It develops combinatory drugs for treatment of diseases such as inflammation, infections, and certain forms of cancer. The firm exploits a novel platform technology for targeted delivery of known drugs to macrophages. The company was founded by Niels Jonas Heilskov Graversen on July 4, 2013 and is headquartered in Aarhus, Denmark. | Pharmaceuticals: Major | Chairman Chairman Director/Board Member | |
Merck Ventures BV
 Merck Ventures BV Investment ManagersFinance Merck Ventures BV (Merck Ventures) is a venture capital arm of Merck KGaA founded in 2009. The firm is headquartered in Amsterdam, the Netherlands. | Investment Managers | Private Equity Analyst Private Equity Investor Private Equity Analyst | |
| ORPHAZYME A/S | Pharmaceuticals: Major | Director/Board Member Corporate Officer/Principal Director/Board Member | |
EpiTherapeutics ApS
 EpiTherapeutics ApS BiotechnologyHealth Technology EpiTherapeutics ApS is a holding company that develops cancer drugs based on research in the field of epigenetics. Its development programs are focused on enzymes involved in the regulation of transcription in cancer - current programs target histone demethylases and methyltransferases. The firm's regulation is commonly used for post-translational covalent modifications of histones and other chromatin-remodeling complexes, which determines whether a gene is accessible and hence, expressed or repressed. Its covalent modifications involved in epigenetic regulation include deoxyribonucleic acid methylation, histone acetylation, and histone methylation. The company was founded by Kristian Helin, Paul Andreas Compare Cloos, Jesper Aagaard Christensen, Karl Agger, and Klaus Hansen on September 18, 2008 and is headquartered in Greve, Denmark. | Biotechnology | Director/Board Member Director/Board Member Director/Board Member | |
| University of Oxford | College/University | Undergraduate Degree Doctorate Degree Graduate Degree | |
Minervax ApS
 Minervax ApS Medical SpecialtiesHealth Technology Minervax ApS provides vaccine against streptococci. It utilizes fusion protein, which has proved to elicit good protective immunity. Its vaccine provides protective immunity against many clinically relevant GBS strains. The firm is engages in biotechnology, scientific and technical activities, and research and development. The company was founded in 2010 and is headquartered in Copenhagen, Denmark. | Medical Specialties | Director/Board Member Chairman Director/Board Member | |
LEO Pharma A/S
 LEO Pharma A/S Pharmaceuticals: MajorHealth Technology LEO Pharma A/S develops, manufactures and markets drugs within the area of dermatology and critical care medicine. It supplies medicines to patients suffering from skin infections and diseases such as psoriasis and eczema, thrombosis, kidney disease and cancer. The company was founded by August Kongsted and Anton Antons in 1908 and is headquartered in Ballerup, Denmark. | Pharmaceuticals: Major | Sales & Marketing Director/Board Member Corporate Officer/Principal | |
Novo Ventures 1 A/S
 Novo Ventures 1 A/S Investment ManagersFinance Novo Ventures (Novo Ventures) is a venture capital operating division of Novo Nordisk Fonden. It engages in investment activities. The firm was established in 1999, and is headquartered in Hellerup, Denmark. | Investment Managers | Director of Investments Corporate Officer/Principal Private Equity Analyst | |
LimmaTech Biologics AG
 LimmaTech Biologics AG Miscellaneous Commercial ServicesCommercial Services LimmaTech Biologics AG is a clinical stage biopharmaceutical company based in Schlieren, Switzerland. LimmaTech Biologics is dedicated to combating the antimicrobial resistance epidemic by developing vaccines using its proprietary self-adjuvanting and multi-antigen vaccine platform, alongside additional disease-specific vaccine approaches. The Swiss company has decades of expertise and an expanding pipeline, and is focused on generating protective solutions to deliver transformative value worldwide. The company was founded in 2015 by Philippe Dro, Michael Wacker, Paul Wolfarm, Michael Kowarik, Veronica Gambillara Fonck. Franz-Werner Haas has been the CEO of the company since 2023. | Miscellaneous Commercial Services | Founder Director/Board Member Founder | |
Metabomed Ltd.
 Metabomed Ltd. Pharmaceuticals: MajorHealth Technology Metabomed Ltd. operates as a drug discovery company. It focuses in the field of cancer metabolism with a proprietary target identification platform based on computational biology and metabolomics. The company was founded by Eytan Ruppin, Tomer Shlomi and Eyal Gottlieb in 2013 and is headquartered in Yavne, Israel. | Pharmaceuticals: Major | Director/Board Member Chief Executive Officer | |
Luciole Medical AG
 Luciole Medical AG Packaged SoftwareTechnology Services Luciole Medical AG operates as a Swiss medical technology company developing brain oxygenation monitoring systems. The firm's products include Rheopatch, RheoSens, RheoLity and RheoControl. The company was founded in September 2017 and is headquartered in Zurich, Switzerland. | Packaged Software | Director/Board Member Chief Executive Officer | |
| University of Utrecht | College/University | Doctorate Degree Graduate Degree | |
INKEF Capital BV
 INKEF Capital BV Investment ManagersFinance INKEF Capital BV is an Independent Venture Capital firm founded in 2010 by Frank R Landsberger. INKEF Capital BV is headquartered in Amsterdam. | Investment Managers | Private Equity Investor Private Equity Investor | |
Comet Therapeutics, Inc.
 Comet Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Comet Therapeutics, Inc. develops and commercializes treatments for patients suffering from metabolic, neurological and immunological disorders. The company was founded by Angellina Sekirnik and Enej Kuscer in 2008 and is headquartered in Cambridge, MA. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
Acesion Pharma ApS
 Acesion Pharma ApS Pharmaceuticals: MajorHealth Technology Acesion Pharma ApS develops drugs for the treatment of atrial fibrillation (AF), the most common type of cardiac arrhythmia. The firm's technology blocks ion channel with a selective drug molecule constitutes a target for developing treatment of AF. The company was founded by Ulrik Svane S?rensen and Morten Grunnet in 2011 and is headquartered in Copenhagen, Denmark. | Pharmaceuticals: Major | Chairman Director/Board Member | |
Asceneuron SA
 Asceneuron SA Pharmaceuticals: MajorHealth Technology Asceneuron SA operates as a biotechnology company. It develops therapeutics for orphan tauopathis and Alzheimer?s disease. The firm specializes in small molecule drug discovery for neurodegenerative diseases. The company was founded by Dirk Beher, Frank Murdoch Armstrong and Christoph Wiessner in October 2012 and is headquartered in Lausanne, Switzerland. | Pharmaceuticals: Major | Chairman Director/Board Member | |
Varmx BV
 Varmx BV BiotechnologyHealth Technology VarmX BV is a spin-off from Leiden University Medical Center (LUMC) founded in 2016 by Professor Pieter Reitsma, a world-leading expert in hemostasis and thrombosis. VarmX is based in Leiden, NL. The Dutch company's lead compound, VMX-C001, is a modified recombinant blood factor X developed for the treatment of severe spontaneous bleeding and for the prevention of bleeding during urgent surgery in patients taking oral factor Xa inhibitors (FXa DOACs) as anticoagulation therapy. The company is supported by a strong syndicate of investors. Jan K. Öhrström has been the CEO of the company since 2018. | Biotechnology | Director/Board Member Director/Board Member | |
| SYNCONA LIMITED | Investment Trusts/Mutual Funds | Private Equity Investor Chief Executive Officer | |
Dansk Biotek
 Dansk Biotek Miscellaneous Commercial ServicesCommercial Services Dansk Biotek is an industry association for biotech companies with promoting the biotechnological research, development and production in taking care of corporate interests in this regard, both nationally and internationally. The company was founded in 1987 and is headquartered in Copenhagen, Denmark. | Miscellaneous Commercial Services | Director/Board Member Director/Board Member | |
NodThera Ltd.
 NodThera Ltd. BiotechnologyHealth Technology NodThera Ltd. researches and develops novel inhibitors of the NLRP3 inflammasome. The company is headquartered in Little Chesterford, the United Kingdom. | Biotechnology | Director/Board Member Director/Board Member | |
Symphogen A/S
 Symphogen A/S Pharmaceuticals: MajorHealth Technology Symphogen A/S provides antibody therapeutics for the treatment of cancers. It offers oncology products and creates selected antibody mixtures that address multiple oncology targets in a single drug product. The firm’s pipeline is fueled by its technology suite capable of identifying, selecting, manufacturing, and characterizing optimal antibody mixtures. The company was founded by Kirsten Aarup Drejer, Thomas Feldthus, Eigil Bjerl Nielsen, Anker Gunvald Lundemose, Kim Arthur Hueg, and John Soerensen Haurum in 2000 and is headquartered in Ballerup, Denmark. | Pharmaceuticals: Major | Chairman Director/Board Member | |
Genentech, Inc.
 Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | Biotechnology | Treasurer Corporate Officer/Principal | |
Galecto Biotech ApS
 Galecto Biotech ApS Pharmaceuticals: MajorHealth Technology Galecto Biotech ApS provides galectin modulators for the treatment of severe diseases, including fibrosis and cancer. Its products include galectin-3 inhibitors, fibrosis and literature. The company was founded by Tariq Sethi, Hans Thalsgard Schambye, Ulf Jorgen Nilsson, and Hakon Leffler in 2011 and is headquartered in Copenhagen, Denmark. | Pharmaceuticals: Major | Director/Board Member Corporate Officer/Principal | |
Sunstone Capital A/S
 Sunstone Capital A/S Investment ManagersFinance Sunstone Capital A/S (Sunstone) is an independent venture capital firm headquartered in Copenhagen, Denmark. The firm was founded in 2007 by Peter Benson, Sten Verland, and Søren Lemonius, and invests on behalf of a group of institutional investors. | Investment Managers | Private Equity Investor Private Equity Investor | |
Schering-Plough Corp.
 Schering-Plough Corp. Pharmaceuticals: MajorHealth Technology Schering Plough Corp. manufactures and sells pharmaceuticals, consumer and animal health care products. The firm discovers, develops, manufactures and markets advanced drug therapies. The company is headquartered in Kenilworth, NJ. | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal | |
Roche Innovation Center Copenhagen A/S
 Roche Innovation Center Copenhagen A/S Pharmaceuticals: MajorHealth Technology Roche Innovation Center Copenhagen A/S discovers and develops drugs for the treatment of oncology, metabolic diseases, and infectious diseases. The firm manufactures a pipeline of drug candidates that act selectively on disease-related ribonucleic acid to provide patients with novel treatments for both rare and common diseases. It produces pre-clinical and clinical assets for the treatment of a range of diseases including oncology, metabolic diseases, and infectious diseases. The company was founded by Matts Lundwall and Mikael Ørum on January 1, 1998 and is headquartered in Horsholm, Denmark. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
7TM A/S
 7TM A/S Pharmaceuticals: MajorHealth Technology 7TM A/S performs research and development within biotechnology. It engages in clinical development of drugs focusing on obesity and gastrointestinal diseases. The company was founded by Thue Walter Schwartz, Anders Fink Vadsholt, Mette Kirstine Agger, Christian Ellebæk Elling, and Peter Moldt on January 1, 2000 and is headquartered in Hørsholm, Denmark. | Pharmaceuticals: Major | Director/Board Member Founder | |
| ALIGOS THERAPEUTICS, INC. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
| OREXO AB | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
Escient Pharmaceuticals, Inc.
 Escient Pharmaceuticals, Inc. BiotechnologyHealth Technology Escient Pharmaceuticals, Inc. operates as a bio-technology company. It develops in-class G Protein-Coupled Receptor targeted drugs to address serious, unserved medical needs. The company was founded by Alain D. Baron, Marcus F. Boehm and Xinzhong Dong and is headquartered in San Diego, CA. | Biotechnology | Director/Board Member Chairman | |
Afferent Pharmaceuticals, Inc.
 Afferent Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Afferent Pharmaceuticals, Inc. develops selective drugs for the treatment of debilitating neurogenic disorders. It offers programs for respiratory, cardiovascular, chronic pain, biology, and clinical trials. The firm offers drugs for osteoarthritis pain, treatment-refractory chronic cough, and interstitial cystitis or bladder pain syndrome. The company was founded by Anthony P. Ford in December 2009 and is headquartered in San Mateo, CA. | Pharmaceuticals: Major | Director/Board Member Chief Executive Officer | |
Plexxikon, Inc.
 Plexxikon, Inc. Miscellaneous Commercial ServicesCommercial Services Plexxikon, Inc. provides clinical and medical drug discovery and development services. The company was founded by Joseph P. Schlessinger, Thomas Richard Kassberg, Sung-hou Kim and K. Peter Hirth in 2001 and is headquartered in Berkeley, CA. | Miscellaneous Commercial Services | Founder President | |
| University of Uppsala | College/University | Undergraduate Degree Masters Business Admin | |
Hoba Therapeutics ApS
 Hoba Therapeutics ApS BiotechnologyHealth Technology Hoba Therapeutics ApS engages in research and experimental development in biotechnology. The firm’s purpose is commercialization of pharmaceuticals and biotechnology services. The company was founded on November 28, 2016 and is headquartered in Copenhagen, Denmark. | Biotechnology | Director/Board Member Director/Board Member | |
| NICOX SA | Pharmaceuticals: Major | Director/Board Member Chief Executive Officer | |
Inthera Bioscience AG
 Inthera Bioscience AG BiotechnologyHealth Technology Inthera Bioscience AG engages in the research in as well as development, production, and distribution of pharmaceutical, biological, and other products used in the fields of human and veterinary medicine. It also provides related consultancy services. The company was founded by Ulrich Kessler and Paramjit Singh Arora on September 20, 2013 and is headquartered in Zurich, Switzerland. | Biotechnology | Director/Board Member Director/Board Member | |
| Royal Institute of Technology | College/University | Graduate Degree Graduate Degree |
Statistics
International
| Denmark | 24 |
| United States | 8 |
| Netherlands | 6 |
| Switzerland | 6 |
| United Kingdom | 5 |
Sectoral
| Health Technology | 34 |
| Finance | 7 |
| Consumer Services | 7 |
| Commercial Services | 4 |
| Technology Services | 2 |
Operational
| Director/Board Member | 332 |
| Corporate Officer/Principal | 86 |
| Chairman | 73 |
| Chief Executive Officer | 54 |
| Independent Dir/Board Member | 41 |
Most connected contacts
| Insiders | |
|---|---|
| Göran Albert Ando | 44 |
| Claus Asbjørn Andersson | 41 |
| Stéphane Verdood | 32 |
| Sten Scheibye | 31 |
| Nanna Liebach Lüneborg | 29 |
| Roel Bulthuis | 29 |
| Ingelise Saunders | 28 |
| Samir Kamal | 27 |
| Bobby G. Soni | 23 |
| Søren Møller | 21 |
| Henrijette Richter | 21 |
| Emmanuelle Coutanceau | 21 |
| Edward van Wezel | 20 |
| K. Hirth | 18 |
| Philippe Dro | 18 |
- Stock Market
- Insiders
- Stephan Christgau
- Company connections
